Multiomics Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures, Licensing and Monetization, Peer Comparison Analysis, Leadership and Governance

Multiomics Manufacturers and Recent Developments

The global multiomics market size is calculated at US$ 2.76 in 2024, grew to US$ 3.18 billion in 2025, and is projected to reach around US$ 11.46 billion by 2034. The market is expanding at a CAGR of 15.32% between 2024 and 2034.

Top Companies in the Multiomics Market

• BD
• Thermo Fisher Scientific, Inc.
• Illumina, Inc
• Danaher (Beckman Coulter)
• PerkinElmer, Inc
• Shimadzu Corporation
• Bruker
• QIAGEN
• Agilent Technologies, Inc.
• BGI Genomics

Multiomics Market Trends

• In November 2024, the healthcare startup PrognomiQ, which is dedicated to using multi-omics data to revolutionize cancer and other complicated illness monitoring, early therapy selection, and identification, announced that it had raised $34 million in Series D funding.
• In February 2024, the biotechnology startup Freenome, which creates blood tests for early cancer diagnosis, reported that it had raised $254 million from both new and current investors. With the help of the funds, Freenome may further develop the pipeline of customized multi-cancer and single-cancer early detection tests based on its multiomics platform.

Latest Announcements by Industry Leaders

In October 2024, a strategic alliance was established between Singleton Biotechnologies, a pioneer in single-cell multi-omics solutions, and Bioscreen, a well-known distributor of cutting-edge life science products in India. This deal would make Bioscreen the only distributor of Singleron's state-of-the-art single-cell multi-omics products in India.

Recent Developments in the Multiomics Market

• In December 2024, one of the pioneers of high-definition spatial proteomics, Ionpath, announced the release of MIBIslide™ Blue, a revolutionary multimodal imaging tool.
• In July 2024, in order to support the ongoing development of its DNA sequencing and multi-omics technologies, Element Biosciences announced a Series D investment of more than $277 million.
• In February 2024, a £6.7 million fundraising round was announced by Tagomics, a University of Birmingham spinout that is creating a state-of-the-art platform for thorough illness understanding and diagnosis.